Premium
Enalapril: A Long‐acting Angiotensin‐Converting Enzyme Inhibitor
Author(s) -
Borek Mark,
Charlap Shlomo,
Frishman William
Publication year - 1987
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/j.1875-9114.1987.tb04039.x
Subject(s) - enalapril , angiotensin converting enzyme , ace inhibitor , enzyme inhibitor , chemistry , pharmacology , enzyme , medicine , biochemistry , blood pressure
The development of angiotensin‐converting enzyme (ACE) inhibitors is of landmark importance in the understanding and treatment of cardiovascular disorders, particularly hypertension and congestive heart failure. Enalapril has recently joined captopril as an approved, orally active ACE inhibitor. Like captopril, it has been effective in the treatment of hypertension and congestive heart failure, with minimal adverse reactions noted. Differences in pharmacology exist between enalapril and captopril which may prove to be of clinical significance.